Clinical trial
Preoperative Cisplatin in Early Stage Breast Cancer
NCT00148694 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00148694 |
|---|---|
| Title | Preoperative Cisplatin in Early Stage Breast Cancer |
| Official title | A Phase II Trial of Cisplatin in Early Stage ER-, PR-, HER-2 Negative Breast Cancer |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Beth Israel Deaconess Medical Center Massachusetts General Hospital Brigham and Women's Hospital Breast Cancer Research Foundation |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Cisplatin |
| Enrollment | 27 |
| Start date | Jul 1, 2004 |
| Primary completion | May 1, 2006 |
| Completion | May 1, 2010 |
| First posted | Sep 8, 2005 |
| Last update posted | Aug 31, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: